@riley_kitch's 42-week Wegovy update, fact-checked

What does this video actually claim?

Riley Kitch shares a personal update after 42 weeks on Wegovy (semaglutide 2.4mg) for weight loss. The TikTok focuses on her individual experience rather than making broad medical claims about the medication's effects.

While the video doesn't make specific numerical claims about weight loss percentages or timelines, it presents her journey as a positive experience. She's documenting her progress at the 42-week mark, which is well beyond the typical clinical trial endpoints we see in published research.

The hashtags suggest this is part of ongoing documentation of her semaglutide experience. Personal testimonials like this are common on social media, though they don't replace clinical evidence.

How does 42 weeks compare to clinical trial data?

The STEP 1 trial (Wilding et al., NEJM, 2021) followed participants for 68 weeks and found 14.9% weight loss with 2.4mg semaglutide versus 2.4% with placebo. Riley's 42-week timeline puts her about two-thirds through that study period.

Most participants in STEP 1 reached their maximum weight loss between weeks 60-68. At week 40, the closest data point to Riley's timeline, participants had achieved roughly 80% of their total weight loss.

The STEP trials used a 68-week endpoint specifically because weight loss with semaglutide continues beyond the typical 6-month mark seen with other interventions. Riley's timing matches when clinical trial participants were still seeing benefits.

What's missing from this personal testimonial?

Riley doesn't discuss side effects, which occurred in 74.2% of semaglutide participants in STEP 1. The most common were nausea (44%), diarrhea (30%), and vomiting (24%).

She also doesn't mention the lifestyle interventions that were part of the clinical trials. STEP 1 participants received counseling sessions every 4 weeks and followed a 500-calorie deficit diet with 150 minutes of weekly exercise.

Personal testimonials can't show whether someone would have achieved similar results with lifestyle changes alone. The placebo group in STEP 1, who received the same counseling and diet recommendations, lost 2.4% body weight without medication.

What should you know about long-term semaglutide use?

The STEP 5 trial (Garvey et al., Obesity, 2022) followed participants for 104 weeks and found that weight loss plateaued around week 68. After that point, participants maintained their weight loss rather than continuing to lose.

Weight regain is common when people stop semaglutide. The STEP 1 extension study showed participants regained about two-thirds of their lost weight within a year of stopping treatment.

Insurance coverage remains inconsistent for weight management indications. Many patients face monthly costs of $1,200-$1,400 without coverage, making long-term use financially challenging for many people.